Actavis said that it intends to use the Allergan name as its corporate name and for its global branded pharmaceutical portfolio, but will retain the Actavis name for select geographic regions and product portfolios.
The change in corporate name would be subject to approval by Actavis' shareholders at its annual general meeting later this year.
CEO and president of Actavis, Brent Saunders, said that the pending combination of Actavis and Allergan would create “a dynamic new breed of company – a leader in Growth Pharma.”
Mr Saunders added: “By adopting the Allergan name, we will ensure that our corporate identity reflects the dramatic evolution of our company within the pharmaceutical industry.
“For more than 65 years, the Allergan name has represented innovation in branded pharmaceuticals, a commitment to bringing the best medicine to life and a strong partnership with physicians.
“The Actavis name has represented our global commitment to leadership in generic, branded generic and over the counter pharmaceuticals and to increased access to more affordable prescription medicine for consumers around the world.”
“Together, our combined company will be equally focused on developing new medicines that meet unmet medical needs in critical therapeutic categories, as well as increasing global access to high quality, affordable medicines,” he concluded.